Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

493
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
493
Cancer Vaccines01:30

Cancer Vaccines

347
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
347
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Cancer Therapies02:49

Cancer Therapies

7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K
siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

16.7K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
16.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

An extracellular, optogenetic antibody platform for stimulus-gated antigen recognition and modulation of cell behavior.

Cell chemical biology·2026
Same author

Transcription Factor Pet-1/FEV as a Potential Therapeutic Target in Anxiety and Depressive Disorders.

CNS & neurological disorders drug targets·2026
Same author

Durumamide A Inhibits NLRP3 Assembly, Limiting Pro-Inflammatory Signaling in Human Gingival Fibroblasts.

Journal of periodontal research·2026
Same author

Unlocking IL-33: New Insights into Tumor Immunity.

Immune network·2025
Same author

Therapeutic potential of polysaccharides in inflammation: current insights and future directions.

International immunopharmacology·2025
Same author

Surfactant-free synthesis of gold nanoparticle-decorated poly(<i>o</i>-phenylenediamine) sub-microspheres as surface-confined signaling probes for label-free electrochemical immunosensing of <i>E. coli O157:H7</i>.

Journal of materials chemistry. B·2025

Related Experiment Video

Updated: Jun 14, 2025

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

9.4K

Engineering interferons for cancer immunotherapy.

Juhee Lim1, Heung Kyu Lee2

  • 1Laboratory of Host Defenses, Department of Biological Sciences, Korea Advanced Institute of Science and Technology (KAIST), Daejeon 34141, Republic of Korea; Graduate School of Medical Science and Engineering, KAIST, Daejeon 34141, Republic of Korea.

Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie
|September 7, 2024
PubMed
Summary
This summary is machine-generated.

Interferon (IFN) therapies show promise for cancer treatment. Cytokine engineering enhances delivery of type I and type III IFNs to tumors, but challenges remain for safe clinical use.

Keywords:
Cytokine engineeringImmunotherapyInterferon-based therapiesTumor microenvironmentType I interferonsType III interferons

More Related Videos

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
10:00

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

Published on: March 24, 2015

13.3K
Experimental Infection with Listeria monocytogenes as a Model for Studying Host Interferon-&#947; Responses
10:10

Experimental Infection with Listeria monocytogenes as a Model for Studying Host Interferon-γ Responses

Published on: November 16, 2016

13.6K

Related Experiment Videos

Last Updated: Jun 14, 2025

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

9.4K
High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
10:00

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

Published on: March 24, 2015

13.3K
Experimental Infection with Listeria monocytogenes as a Model for Studying Host Interferon-&#947; Responses
10:10

Experimental Infection with Listeria monocytogenes as a Model for Studying Host Interferon-γ Responses

Published on: November 16, 2016

13.6K

Area of Science:

  • Immunology
  • Oncology
  • Biotechnology

Background:

  • Interferons (IFNs) are cytokines crucial for immunity.
  • Type I IFNs have broad effects and are explored for cancer therapy.
  • Type III IFNs offer potential for targeted cancer treatment with fewer side effects.

Purpose of the Study:

  • To review the development of IFN-based therapeutics for cancer.
  • To highlight advancements in cytokine engineering for IFN delivery.
  • To identify remaining obstacles for clinical application of IFN therapies.

Main Methods:

  • Review of existing literature on Type I and Type III IFNs in cancer.
  • Analysis of cytokine engineering strategies for targeted delivery.
  • Discussion of clinical challenges and future directions.

Main Results:

  • IFN-based therapies are being developed for various tumors.
  • Cytokine engineering enables improved delivery of IFNs to tumor sites.
  • Type III IFNs present a potentially safer alternative due to specific receptor expression.

Conclusions:

  • IFN-based cancer therapies are advancing through cytokine engineering.
  • Further research is needed to overcome toxicity and efficacy challenges for clinical integration.
  • Type III IFNs may offer a more targeted approach to cancer immunotherapy.